Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

pembrolizumab 8Sunitinib 7enfortumab vedotin 6Abiraterone Acetate 6enzalutamide 5Nivolumab 5Gemcitabine 5Cisplatin 5Carboplatin 4avelumab 3Prednisone 3Ipilimumab 3Docetaxel 3Androgen Antagonists 3sacituzumab govitecan 2olaparib 2niraparib 2erdafitinib 2entrectinib 2durvalumab 2darolutamide 2cabozantinib 2belzutifan 2apalutamide 2Pluvicto 2Mitomycin 2Leuprolide 2Everolimus 2Axitinib 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × ALT-803 × Genitourinary × Clear all
NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

ImmunityBio, Inc.

Phase 2/3 Active not recruiting
190 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡